Type 2 diabetes with mild cognitive disfunction
Conditions
Interventions
Lixisenatide administration
ultra-rapid insulin administration
Sponsors
Tokyo medical university, Department of Medicine, Division of Diabetes, Metabolism and Endocrinology, Department of Gerontology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Type 2 diabetes treated with Basal insulin with/without oral antidiabetic agents for more than 3 months 2.Patients whose taken SU is discontinued 3.Patients whose HbA1c 7.0% <= HbA1c < 10.0% at the enrollment 4.Patients whose FPG 110mg/dl <= FPG < 180mg/dl 5. Patients without severe cardiac disease,severe hepatic disorder,severe renal disease. 6. Patients who can possess the agreement ability and get consent by a document 7. Patients who can understand consent brief and other explanation documents having the ability of the agreement about participation in this examination 8.Outpatients
Exclusion criteria
Exclusion criteria: 1.Patients who are not Type 2 diabetes 2.Excessive common custom drinker 3.Patients having a cancer 4. Patients with severe diabetic complication. 5.Patients with severe renal disease or severe liver disease 6. History of chemical sensitivity to antidiabetic drugs. 7. Women who are pregnant or nursing or could become pregnant. 8. Determined to be ineligible by the physician in charge for any other reason.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of cognitive function(MMSE,DSST,Moca-J,GDS-15,TMT-A,TMT-B) | — |
Secondary
| Measure | Time frame |
|---|---|
| Change of cerebral blood flow(MRI,SPECT) Blood glucose(HbA1c,Fasting blood glucose, post-prandial blood glucose, SMBG) Glycoalbumin, 1,5-anhydroglcitol, C-peptide, hypoglycemic episode, QOL(DTSQ) | — |
Countries
Japan
Contacts
Public ContactMasato Odawara
Tokyo medical university hospital Department of Medicine, Division of Diabetes, Metabolism and Endocrinology
Outcome results
None listed